AstraZeneca, through its Alexion subsidiary, has entered an agreement to acquire LogicBio Therapeutics, Inc. for $68 million, enhancing AstraZeneca’s efforts in genomics and rare diseases.
 
Lexington, MA-based LogicBio, is a clinical-stage genomic medicine company with unique technology, experienced rare disease R&D team, and expertise in preclinical development, which will support Alexion’s growth in genomic medicines. Alexion plans to retain LogicBio employees at their current location.
 
Fred Chereau, President and Chief Executive Officer, LogicBio, said: “We are excited about the opportunity to bring our science and expertise in genetic medicine to Alexion, which shares our commitment to discovering treatments for rare conditions and improving the lives of patients. Through this acquisition, we strive to accelerate our research in gene editing and AAV capsid development and together move the field of genomic medicine forward.”
 
LogicBio has developed technology platforms for the delivery and insertion of genes to address genetic diseases, as well as a platform designed to improve viral vector manufacturing processes. These platforms, along with LogicBio’s highly experienced team and Alexion’s advancements with AstraZeneca, aim to drive next generation medicines to treat rare genetic diseases.
 
“The proposed acquisition of LogicBio is a significant development for our growing research in genomic medicine,” said Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease. “LogicBio’s people, experience and platforms provide new scientific capabilities by adding best-in-class technology and expertise to our genomic medicine strategy. The scientific collaboration between Alexion and AstraZeneca has been a substantial area of focus since last year’s acquisition and the addition of LogicBio will expand this foundational work.”